Aztreonam for inhalation solution, challenges to drug approval and integration into CF care

Journal of Cystic Fibrosis

Volumn 12, Issue 2, 2013, Pages 99-101

  Goss, Christopher H ^a,b   Bell, Scott C ^c,d,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; IMIPRAMINE; NOMIFENSINE; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; EDITORIAL; FORCED EXPIRATORY VOLUME; FUNDING; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; CYSTIC FIBROSIS; FEMALE; MALE; MICROBIOLOGY; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 84878016233     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.08.006     Document Type: Editorial

References (13)

1. Fleming T.R. Design and interpretation of equivalence trials. Am Heart J 2000, 139(4):S171-S176.
2. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003, 22(2):169-186.
3. Hung H.M., Wang S.J., O'Neill R. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biom J 2009, 51(2):324-334.
4. Temple R., Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000, 133(6):455-463.
5. Ellenberg S.S., Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000, 133(6):464-470.
6. Quittner A.L., Modi A.C., Wainwright C., Otto K., Kirihara J., Montgomery A.B. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009, 135(6):1610-1618.
7. Committee for medicinal Products for Human Use Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. Doc. ref. EMEA/CHMP/EWP/9147/2008 10-22-2009, European Medicines Agency, London.
8. Temple R. How FDA currently makes decisions on clinical studies. Clin Trials 2005, 2(4):276-281.
9. Regulatory watch: non-inferiority-trial discussions impact new drug applications. Nat Rev Drug Discov 2009, 8(1):10.
10. McCormick J., Mehta G., Olesen H.V., Viviani L., Macek M., Mehta A. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010, 375(9719):1007-1013.
11. Vella S., Schwartlander B., Sow S.P., Eholie S.P., Murphy R.L. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 2012, 26(10):1231-1241.
12. Buse K., Martin G. AIDS: ushering in a new era of shared responsibility for global health. Glob Health 2012, 8(1):26.
13. Assael B.M., Pressler T., Bilton D., Fayon M., Fischer R., Chiron R., et al. AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013, 12(2):130-140.